Outlook Therapeutics, Inc. Common Stock
Here’s whether Outlook Therapeutics, Inc. Common Stock (OTLK) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+0.93% over 10 days); RSI 35 — healthy momentum range; 3-month momentum positive (+108.8%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -73.2%; rising volume on a downtrend (distribution, 1.69x avg). Currently 80.9% off its 52-week high. Score: -1/7.
OTLK is trading below its 200-day MA ($0.90) — a key warning sign the longer-term trend is under pressure. An RSI of 35.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -73.2% compares to +20.5% for SPY (trailed the market by 93.6%). The current 80.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.